FDA Cracks Down on Hims & Hers and Other Telehealth Companies for Marketing Unofficial Weight-Loss Drugs
Novo Nordisk Shares Rise After Positive Phase 3 Trial Results for Experimental Weight-Loss Injection Cagrilintide, Offering New Hope in Obesity Treatment Market
Wegovy Trial Data Lifts Novo Nordisk as U.S. Market Challenges Weigh on Growth
GoodRx Stock Surges After Novo Nordisk GLP-1 Deal at $499/Month
Novo Nordisk Stock Craters as Wegovy and Ozempic Forecasts Get Slashed
Pump Radar
Stock Alerts